Cargando…
Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Patients with advanced chronic kidney disease (CKD), including those treated with dialysis, are at high risk for the development of cardiovascular disease (CVD). CVD accounts for 45-50% of deaths among dialysis patients. Therapy of acute and chronic coronary heart disease (CHD) that is effective in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558358/ https://www.ncbi.nlm.nih.gov/pubmed/25981315 http://dx.doi.org/10.2174/1573403X1103150514155757 |
_version_ | 1782388604801122304 |
---|---|
author | Agrawal, Harsh Aggarwal, Kul Littrell, Rachel Velagapudi, Poonam Turagam, Mohit K. Mittal, Mayank Alpert, Martin A. |
author_facet | Agrawal, Harsh Aggarwal, Kul Littrell, Rachel Velagapudi, Poonam Turagam, Mohit K. Mittal, Mayank Alpert, Martin A. |
author_sort | Agrawal, Harsh |
collection | PubMed |
description | Patients with advanced chronic kidney disease (CKD), including those treated with dialysis, are at high risk for the development of cardiovascular disease (CVD). CVD accounts for 45-50% of deaths among dialysis patients. Therapy of acute and chronic coronary heart disease (CHD) that is effective in the general population is frequently less effective in patients with advanced CKD. Drug therapy in such patients may require dose modification in some cases. Oral anti-platelet drugs are less effective in those with advanced CKD than in persons with normal or near normal renal function. The intravenous antiplatelet drugs eptifibatide and tirofiban both require dose reductions in patients with advanced CKD. Enoxaparin requires dose reduction in early stage CKD and is contraindicated in hemodialysis patients. Unfractionated heparin and warfarin maybe used without dose adjustment in CKD patients. Atenolol, acetbutolol and nadolol may require dose adjustments in CKD. Metoprolol and carvedilol do not. Calcium channel blockers and nitrates do not require dose adjustment, whereas ranolazine does. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers may safely be used in CKD patients with close observation for hyperkalemia. The safety of spironolactone in such patients is questionable. Statins are less effective in reducing cardiovascular complication in CKD patients and their initiation is not recommended in dialysis patients. Coronary artery bypass grafting is associated with higher short-term mortality, but better long-term morbidity and mortality than percutaneous coronary interventions in patients with advanced CKD with non-ST segment ACS and chronic CHD. |
format | Online Article Text |
id | pubmed-4558358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-45583582016-08-01 Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease Agrawal, Harsh Aggarwal, Kul Littrell, Rachel Velagapudi, Poonam Turagam, Mohit K. Mittal, Mayank Alpert, Martin A. Curr Cardiol Rev Article Patients with advanced chronic kidney disease (CKD), including those treated with dialysis, are at high risk for the development of cardiovascular disease (CVD). CVD accounts for 45-50% of deaths among dialysis patients. Therapy of acute and chronic coronary heart disease (CHD) that is effective in the general population is frequently less effective in patients with advanced CKD. Drug therapy in such patients may require dose modification in some cases. Oral anti-platelet drugs are less effective in those with advanced CKD than in persons with normal or near normal renal function. The intravenous antiplatelet drugs eptifibatide and tirofiban both require dose reductions in patients with advanced CKD. Enoxaparin requires dose reduction in early stage CKD and is contraindicated in hemodialysis patients. Unfractionated heparin and warfarin maybe used without dose adjustment in CKD patients. Atenolol, acetbutolol and nadolol may require dose adjustments in CKD. Metoprolol and carvedilol do not. Calcium channel blockers and nitrates do not require dose adjustment, whereas ranolazine does. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers may safely be used in CKD patients with close observation for hyperkalemia. The safety of spironolactone in such patients is questionable. Statins are less effective in reducing cardiovascular complication in CKD patients and their initiation is not recommended in dialysis patients. Coronary artery bypass grafting is associated with higher short-term mortality, but better long-term morbidity and mortality than percutaneous coronary interventions in patients with advanced CKD with non-ST segment ACS and chronic CHD. Bentham Science Publishers 2015-08 2015-08 /pmc/articles/PMC4558358/ /pubmed/25981315 http://dx.doi.org/10.2174/1573403X1103150514155757 Text en © 2015 Bentham Science Publishers http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Agrawal, Harsh Aggarwal, Kul Littrell, Rachel Velagapudi, Poonam Turagam, Mohit K. Mittal, Mayank Alpert, Martin A. Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease |
title | Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease |
title_full | Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease |
title_fullStr | Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease |
title_full_unstemmed | Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease |
title_short | Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease |
title_sort | pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558358/ https://www.ncbi.nlm.nih.gov/pubmed/25981315 http://dx.doi.org/10.2174/1573403X1103150514155757 |
work_keys_str_mv | AT agrawalharsh pharmacologicalandnonpharmacologicalstrategiesinthemanagementofcoronaryarterydiseaseandchronickidneydisease AT aggarwalkul pharmacologicalandnonpharmacologicalstrategiesinthemanagementofcoronaryarterydiseaseandchronickidneydisease AT littrellrachel pharmacologicalandnonpharmacologicalstrategiesinthemanagementofcoronaryarterydiseaseandchronickidneydisease AT velagapudipoonam pharmacologicalandnonpharmacologicalstrategiesinthemanagementofcoronaryarterydiseaseandchronickidneydisease AT turagammohitk pharmacologicalandnonpharmacologicalstrategiesinthemanagementofcoronaryarterydiseaseandchronickidneydisease AT mittalmayank pharmacologicalandnonpharmacologicalstrategiesinthemanagementofcoronaryarterydiseaseandchronickidneydisease AT alpertmartina pharmacologicalandnonpharmacologicalstrategiesinthemanagementofcoronaryarterydiseaseandchronickidneydisease |